ROS1 and non-small cell lung carcinoma: Furthermore, CD74-ROS1 is the most common form of ROS1 fusion in NSCLC, and CD74-NRG1 gene fusion activates genomic alterations in aggressive mucinous adenocarcinomas, offering potential therapeutic opportunities for lung tumor subtypes that have not yet been effectively treated (17).